Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE versus CARVEDILOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE versus CARVEDILOL.
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE vs CARVEDILOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine is an amide local anesthetic that blocks sodium channels, inhibiting nerve impulse conduction. Epinephrine is a vasoconstrictor that prolongs bupivacaine's effect by reducing vascular absorption.
Carvedilol is a nonselective beta-adrenergic receptor antagonist (beta-1, beta-2) and alpha-1 adrenergic receptor antagonist. It causes vasodilation and reduces heart rate, myocardial contractility, and blood pressure. It also has antioxidant and anti-proliferative effects.
Maximum dose of bupivacaine: 2 mg/kg (not to exceed 175 mg); with epinephrine: 3 mg/kg (not to exceed 225 mg). Administer via local infiltration, peripheral nerve block, epidural, or caudal block. Dose depends on the anesthetic procedure. Repeated doses may be given at intervals of 3-6 hours. Maximum single dose for epidural: 50 mg initially, then 10-25 mg per segment as needed.
Heart failure: Initial 3.125 mg orally twice daily, titrate every 2 weeks to 6.25 mg, 12.5 mg, then 25 mg twice daily as tolerated. Target dose: 25 mg twice daily (≤85 kg) or 50 mg twice daily (>85 kg). Hypertension: Initial 6.25 mg orally twice daily, titrate every 1-2 weeks to 12.5 mg, then 25 mg twice daily. Maximum: 50 mg twice daily.
None Documented
Clinical Note
moderateCarvedilol + Digitoxin
"Carvedilol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateCarvedilol + Deslanoside
"Carvedilol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateCarvedilol + Acetyldigitoxin
"Carvedilol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateCarvedilol + Ouabain
"Carvedilol may increase the bradycardic activities of Ouabain."
None Documented
Terminal elimination half-life of bupivacaine is approximately 2.7 hours (range 1.5–5.5 hours) in adults. In neonates, half-life is prolonged (8–12 hours) due to immature hepatic function. The half-life of epinephrine is very short (~1–2 minutes) due to rapid metabolism.
Terminal elimination half-life is 7-10 hours. Steady-state concentrations are achieved within 2-3 days. Clinical context: Twice-daily dosing provides consistent beta-blockade and vasodilation.
Bupivacaine is primarily metabolized in the liver via CYP3A4 and is excreted renally as metabolites (approximately 95% in urine) and less than 5% unchanged. Epinephrine is rapidly metabolized by COMT and MAO and excreted renally as metabolites.
Primarily hepatic metabolism, with less than 2% excreted unchanged in urine. Metabolites are excreted in bile and feces; renal clearance of metabolites accounts for ~16% of total clearance. Fecal excretion of metabolites is ~60%.
Category A/B
Category C
Alpha/Beta Agonist
Alpha/Beta-Blocker